Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have earned a consensus recommendation of "Hold" from the eighteen analysts that are covering the stock, Marketbeat reports. Three research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and eleven have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $152.21.

Several research firms have issued reports on CRSP. Raymond James restated a "sell" rating on shares of CRISPR Therapeutics in a report on Friday, October 30th. Canaccord Genuity lifted their price objective on CRISPR Therapeutics from $120.00 to $151.00 and gave the stock a "buy" rating in a report on Monday, December 7th. Stifel Nicolaus lifted their price objective on CRISPR Therapeutics from $91.00 to $145.00 and gave the stock a "positive" rating in a report on Monday, December 7th. They noted that the move was a valuation call. Jefferies Financial Group downgraded CRISPR Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, December 10th. They noted that the move was a valuation call. Finally, Royal Bank of Canada began coverage on CRISPR Therapeutics in a report on Thursday, October 22nd. They issued a "sector perform" rating and a $110.00 price target for the company.

In related news, COO Lawrence Otto Klein sold 25,000 shares of the company's stock in a transaction on Friday, January 15th. The stock was sold at an average price of $215.20, for a total transaction of $5,380,000.00. Following the completion of the transaction, the chief operating officer now directly owns 28,666 shares in the company, valued at approximately $6,168,923.20. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Samarth Kulkarni sold 20,000 shares of the company's stock in a transaction on Thursday, December 10th. The stock was sold at an average price of $142.29, for a total value of $2,845,800.00. Following the transaction, the chief executive officer now owns 189,189 shares of the company's stock, valued at $26,919,702.81. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 427,703 shares of company stock valued at $66,444,533. 17.10% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of CRSP. FMR LLC grew its stake in CRISPR Therapeutics by 18.8% during the 2nd quarter. FMR LLC now owns 1,041,810 shares of the company's stock worth $76,563,000 after buying an additional 164,796 shares during the last quarter. Vanguard Group Inc. grew its stake in CRISPR Therapeutics by 79.6% during the 2nd quarter. Vanguard Group Inc. now owns 333,554 shares of the company's stock worth $24,513,000 after buying an additional 147,782 shares during the last quarter. Envestnet Asset Management Inc. acquired a new position in CRISPR Therapeutics during the 3rd quarter worth $337,000. RFG Advisory LLC boosted its position in CRISPR Therapeutics by 29.5% during the 3rd quarter. RFG Advisory LLC now owns 3,894 shares of the company's stock worth $326,000 after acquiring an additional 886 shares during the period. Finally, Nachman Norwood & Parrott Inc acquired a new position in CRISPR Therapeutics during the 3rd quarter worth $42,000. Hedge funds and other institutional investors own 66.43% of the company's stock.

CRSP stock opened at $165.68 on Tuesday. CRISPR Therapeutics has a 52-week low of $32.30 and a 52-week high of $220.20. The stock's 50 day moving average is $173.49 and its two-hundred day moving average is $117.01. The company has a market capitalization of $11.80 billion, a PE ratio of -50.82 and a beta of 2.37.

About CRISPR Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.

Read More: Cash Asset Ratio

Analyst Recommendations for CRISPR Therapeutics (NASDAQ:CRSP)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

12 Marijuana Stocks to Buy Now

There are now more than 50 publicly-traded companies operating in the cannabis industry. Most of these companies aren't directly growing and selling marijuana themselves, but they do stand to benefit greatly as more states legalize the sale and possession of marijuana. Some of these marijuana stocks are media companies. Others are privately studying the medical uses of marijuana. Yet others are providing tools and software for marijuana growers. As more cannabis companies file IPOs and enter the stock market, it will become increasingly difficult for investors to identify which marijuana stocks will truly benefit from the cannabis boom.

Our subscribers have begun digging through these companies, checking out their financials, business models and long-term growth prospects. They know that some "marijuana stocks" are just empty shell companies that deserve to be penny stocks, but they also recognize there are some legitimate and growing companies that truly stand to benefit from the green rush. As a group, they have added 10 different cannabis stocks to their watchlists and are actively investing in them. More than 1,400 MarketBeat subscribers are now following our top-trending cannabis company.

This slide show lists the 12 pot stocks that MarketBeat subscribers are have added to their watchlists and are actively monitoring.

View the "12 Marijuana Stocks to Buy Now".



Source link